Communiqués

24/08 Iconovo: Still waiting for commercial proof – Q2 review AQ
03/07 Iconovo AB (publ) reintroduces liquidity provider agreement with Pareto Securities AB AQ
29/06 Iconovo terminates liquidity provider agreement AQ
22/06 Iconovo and Lonza sign Strategic Collaboration Agreement AQ
24/04 Iconovo: Limited progress – Q1 review AQ
14/04 Anders Månsson is appointed CEO AQ
17/03 Iconovo publishes outcome of exercise of warrants series TO 1 AQ
10/03 Iconovo’s rights issue is registered – conversion of BTA into shares AQ
02/03 Iconovo announces final outcome in the rights issue AQ
27/02 Iconovo publishes preliminary outcome of rights issue and announces recalculation of warrants series TO 1 AQ
24/02 Iconovo and Lonza signs LOI regarding strategic collaboration AQ
16/02 Iconovo: Still needs proof – Q4 review AQ
13/02 Iconovo - Q4 2025 - Intervju AQ
13/02 The subscription period in Iconovo's rights issue begins today AQ
12/02 Iconovo publishes information document regarding rights issue of shares AQ
15/01 Iconovo has initiated a new feasibility study for ICOone® Nasal in collaboration with multinational company AQ
13/01 EPO declares intention to approve ICOpre® patent application AQ
22/12 Nomination Committee appointed at Iconovo AB AQ
16/12 Iconovo announces that the terms and conditions for allotment of shares in directed issue are met AQ
26/11 Iconovo: Raises capital AQ
25/11 Iconovo carries out a directed issue of shares of approx. SEK 25 million and a rights issue of shares of approx. SEK 24.6 million, which is covered to 100% by subscription undertakings and guarantee commitments AQ
31/10/25 Iconovo: New interim CEO appointed AQ
31/10/25 Iconovo appoints new CEO AQ
27/10/25 Iconovo (Q3 Review) - An uneventful quarter with solid cost-cutting AQ
24/10/25 Iconovo: Costs down, focus sharpened – Q3 review AQ
Aucun résultat pour cette recherche